BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

EMD Lexigen Research Center

EMD Lexigen Research Center Corp. Founded in 1992 as a joint venture with Fuji Photo Film Ltd., EMD Lexigen Research Center Corp. (EMD Lexigen for short) was formed to screen Fuji’s chemical library for drug activities, with an initial focus on immune disorders and cancer.
Our activities have evolved significantly since then. Having gained independence from Fuji Photo Film in 1997, EMD Lexigen has honed its activities to focus on developing proprietary immunocytokine and Fc-X fusion protein technologies for treatment of life-threatening diseases such as cancer and AIDS.
EMD Lexigen’s innovative technology and approach to oncology quickly drew the attention of the pharmaceutical community, including Merck KGaA, Darmstadt, Germany, which ultimately acquired EMD Lexigen in 1999.
EMD Lexigen is a subsidiary of Merck KGaA, Darmstadt, Germany. Our research center, located in the Route 128 Biotech Corridor near Boston, Mass., is the hub for Merck KGaA’s biological pharmaceutical research activities, emphasizing advanced pharmaceutical platform technologies and novel drugs.
With access to the Boston area’s rich combination of world-class academic and research institutions and highly skilled workforce, we have built a company that thrives on innovation, with employees dedicated to improving people’s lives.


Contact Details:
45A Middlesex Turnpike
Billerica
Massachusetts
01821
United States of America
Tel:978 294 1100
Fax: 978 294 1101
Email:info@emdlexigen.com
WWW:

www.lexigenpharm.com/




Loading...

Recent Publications by EMD Lexigen Research Center:

huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
IL-12 is a cytokine which showed anti-tumor effects in clinical trials,...
17th May, 2007
EMD Lexigen Research Center, 45A Middlesex Turnpike, Billerica, MA 01821, Cancer Immunol Immunother. 2007 Apr;56(4):447-57. Epub 2006 Jul 28.
DOI Direct Link
Engineering a pharmacologically superior form of leptin for the treatment of obesity.
Leptin plays a central role in the homeostasis of body weight through its...
28th October, 2005
EMD-Lexigen Research Center, Bedford Campus, 45A Middlesex Turnpike, Protein Eng Des Sel. 2005 Jan;18(1):1-10.
DOI Direct Link
Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond.
Erythropoietin (Epo) is a cytokine that controls the production of red...
4th October, 2005
EMD Lexigen Research Center Corp., 45A Middlesex Turnpike, Billerica, MA Protein Eng Des Sel. 2005 Mar;18(3):111-8. Epub 2005 Apr 8.
DOI Direct Link
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
We have engineered an anti-CD20-interleukin 2 (IL-2) immunocytokine (ICK)...
9th June, 2005
EMD Lexigen Research Center, Bedford Campus, 45A Middlesex Tpk, Billerica, Blood. 2005 May 15;105(10):3972-8. Epub 2005 Feb 3.
DOI Direct Link
Immunocytokines: amplification of anti-cancer immunity.
Many cancers elicit an anti-tumor immune response, which is nevertheless...
26th June, 2003
EMD Lexigen Research Center, Billerica, MA 01821, USA. Cancer Immunol Immunother. 2003 May;52(5):297-308. Epub 2003 Jan 31.
DOI Direct Link

View more EMD Lexigen Research Center research publications.

BioNews Results for EMD Lexigen Research Center:

Looking for jobs at DDT
Genetic Engineering News:  Aug 14 2008 6:55AM Matching: emd research center
3rd Investigator Relationship Management Conference- Improving Quality, Reducing Costs and Shortening Timeline
Pharmalive.com:  Jul 26 2008 5:41AM Matching: emd research center

EMD Lexigen Research Center Patents:

US Patent No.Title
7365054 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
6838260 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
6969517 Recombinant tumor specific antibody and use thereof
6992174 Reducing the immunogenicity of fusion proteins
7067110 Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens

View more EMD Lexigen Research Center patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 631 times since April 2007, the link to the organisation's website has been followed 139 times

Recent Search Terms used to find this page: emd lexigen | emd lexigen | EMD Lexigen Research Center Corp | EMD lexigen merk | EMD Lexigen Research Center | emd lexigen | emd lexigen | EMD Lexigen Research Center Corp | 978 294 1100 | emd lexigen research | .

Search for more companies in Billerica

Search for more companies in Massachusetts



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for EMD Lexigen Research Center
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.